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Background: Lipoid proteinosis (LP) is known to be resulted from mutations of the extracellular matrix protein 1 gene
(ECM1). However, no effective or sustained therapeutic methods to alleviate LP symptoms have been reported.
Methods: Here, we report a 12-year-old boy with LP and recurrent anaphylaxis. The laboratory and histopathological
investigations were adopted to confirm the diagnosis, and gene sequencing was performed. We treated this patient
with glucocorticoid for three years to relieve the patient’s lipid metabolism disorder and symptoms related to LP and
anaphylaxis.
Results: The Laboratory and histopathological investigations showed a lipid metabolism disorder and anaphylaxis in
the patient. A homozygous missense mutation p.C220G of ECM1 was identified by Sanger sequencing, which is a
major allele in Chinese patients with LP. Notably, after three years’ treatment, the symptoms such as skin lesions, stiff
oral mucosa and hoarse voice in the patient were significantly relieved or recovered.
Conclusions: Our report may provide a potentially effective therapeutic approach for the first time to other LP patients
who are experiencing recurrent anaphylaxis and/or chronic inflammation.
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Lipoid proteinosis (LP) (OMIM 247100), also known as
Urbach-Wiethe disease, is a rare autosomal recessive
genodermatosis characterized predominantly by hoarse-
ness, variable scarring and infiltration of the skin and
mucosa [1]. LP was first reported by Urbach and Wiethe
in 1929, and originally named ‘lipoidosis cutis et mu-
cosae’. This disorder typically presents warty skin infil-
tration, beaded papules along the eyelid margins, skin
scarring, extracutaneous abnormalities, as well as
hoarseness of the voice, epilepsy and neuropsychiatric
abnormalities [2]. Histologically, there can be widespread
deposition or accumulation of hyaline-like materials and* Correspondence: cai1d8@yahoo.com; wqtzym@fmmu.edu.cn
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unless otherwise stated.disruption or irregular reduplication of basement mem-
brane around blood vessels and at the dermal-epidermal
junction. Since pathological mutations were identified in
the extracellular matrix protein 1 gene (ECM1) in 2002,
more than 50 different cases with ECM1 mutations have
been reported thus far, most of which were specific to
individual families [3]. In this paper, we reported a
homozygous mutation of ECM1 gene in a Chinese boy
with LP and recurrent anaphylaxis. Notably, we present
our experience from a pilot study for treating the patient
with therapeutic glucocorticoid.Methods
Histopathological analysis
Informed consent was obtained from the patient’s par-
ents. Biopsy specimens were taken from the patient’s
thickened and stiff tongue mucosa. Normal mucosa as a
control was obtained from surgical specimens. The spec-
imens were fixed in 10% formalin and processed for rou-
tine light microscopy with paraffin embedding. SectionsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Clinical features of lipoid proteinosis. A. Beaded papules along the eyelids (indicated by an arrow); B. The patient’s tongue was
hypertrophic and stiff; Movement of the tongue was restricted (#); C. The patient’s lower lip was also hypertrophic and stiff, with grainy materials
(*); D. Waxy plaques and fine lines were shown on his buttock (by arrows).
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odic acid–Schiff (PAS).
PCR and Sanger sequencing
Peripheral blood samples were taken from the affected
patient and his parents. DNAs were extracted usingFigure 2 Effects of the treatment. A. Yellowish papular infiltration and fin
rugged scar on the skin of left shoulder (by dots); C. The popular and fine line
became flat, and the skin color also lightened.Gentra Puregene DNA kit (Qiagen, Valencia, CA, USA).
Primers were designed for amplification of all exons of
the ECM1 gene (see Additional file 1). For PCR amplifi-
cation, 250 ng of genomic DNA was used as the
template in an amplification buffer containing 5 pmol of
each primer, 2.5 mmol MgCl2, 0.5 mmol of each nucleosidee lines on the patient’s forehead (indicated by arrows); B. Irregular and
s almost disappeared on the forehead; D. The scar on the left shoulder







Eosinophilic granulocyte 6.50 0.50 (0.02-0.52 ) × 109/L
Basophilic granulocyte 3.30 0.08 (0-0.06) × 109/L
IgE 371.62 79.74 (0-100) IU/mL
ESR* 58 12 (0-15) mm/h
TG† 1.88 1.08 (0.48-1.82) mmol/L
TC‡ 5.15 4.43 (2.80-5.20) mmol/L
HDL§ 0.71 1.66 (0.90-1.83) mmol/L
LDL¶ 4.32 2.62 (0-3.12) mmol/L
*ESR, erythrocyte sedimentation rate; †TG, triglyceride; ‡TC, total cholesterol;
§HDL, high density lipoprotein; ¶LDL, low density lipoprotein.
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(Applied Biosystems, Foster City, CA, USA) in a total
volume of 50 μl in a GeneAmp PCR System 9700 thermal
cycler (Applied Biosystems, Foster City, CA). The amplifi-
cation conditions were 95°C for 5 min, followed by 35 cy-
cles of 95°C for 1 min, annealing temperature (see
Additional file 1) for 45 s, 72°C for 45 s. PCR products
were analyzed by 2.5% agarose gel electrophoresis and
purified using QIAquick PCR Purification Kit (Qiagen,
Valencia, CA, USA) for sequencing in an ABI 310 Genetic
Analyzer (Applied Biosystems, Foster City, CA). The con-
trol samples were selected from 100 normal individuals.
Clinical therapy
All the treatments were approved by the Ethics Commit-
tee of Stomatological Hospital of FMMU, PLA (IRB-
REV-2013006). The patient was treated with 1 ml ofFigure 3 Histological findings of lipoid proteinosis. A. Hyperplasia of th
throughout the lamina propria in the patient’s tongue (*) (by haematoxylin an
vessels (indicated by arrows) (by periodic acid–Schiff, i.e., PAS).compound betamethasone plus equivalent lidocaine by
submucosal injection to the underlip and margo lateralis
linguae monthly for a period of 6 months and were then
administered every 2 months for another 6 months.
After that, the patient was suggested to take hydrocorti-
sone orally in the dosage of 20-25 mg per quadratmeter
of body surface area and locally on the skin lesion every
three days for 2 years. Clinical follow-up was carried out
weekly for another one year to observe the endurance of
the effect (see Additional file 2).
Results
Clinical manifestation
A 12 year-old boy asked for management of sclerosis of
oral mucosa in 2008. The patient was the only child of
his nonconsanguineous parents. The patient had hoarse-
ness since infancy, and experienced recurrent ulcerations
on his oral mucosa and restricted tongue movement
since he was three years old. From the age of 5 years,
the patient had dry skin with numerous waxy plaques
over his occipitalia, back, buttocks and antecubital fossa
and vulnerable to minor trauma. After healing, the
wound was easy to form scars. Moreover, his tongue and
lips gradually became hypertrophic and stiff. Since then
his parents found that the boy began to suffer from re-
current anaphylaxis to many kinds of anaphylactogen
like pollen. Physical examinations revealed beaded eye-
lids papules (Figure 1A), hypertrophic lips and tongue
with white and thicken mucosa (Figure 1B, C). His
tongue was enlarged and restricted by a thickened
frenulum. Waxy, yellow papules and nodules as well as
deepening fine line were also noted on his buttocks and
forehead (Figure 1D, Figure 2A). An irregular scar (aboute mucous epithelium and deposits of homogeneous hyaline-like materials
d eosin staining); B. Hyaline-like materials surrounding several blood
Figure 4 Pedigree and sequencing result. A. Pedigree of the family: the filled box represents the affected child, open box or circle with a dot,
the heterozygote parents. B. Homozygous mutation c.658T > G (p.C220G) of ECM1 exon 6 of the patient. C. Heterozygous mutation of the same
position of his parent. D. Normal DNA sequence of ECM1 exon 6.
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Neurological and psychological examinations were found
to be normal.
Laboratory and histopathological findings
Blood and immunological evaluation revealed incre-
mental levels of eosinophilic granulocytes, basophilicgranulocytes and IgE. Erythrocyte sedimentation rate
(ESR) was elevated. Lipid profile indicated a lipid metab-
olism disorder (Table 1). Acupuncture reaction test was
positive. However, other types of immunoglobulin, C-
reaction protein and autoantibodies were normal. A com-
puterized brain scan (CT scan) and magnetic resonance
imaging (MRI) had no abnormal findings. Video
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glottis and thicken vocal cords. Histologically, a slight
hyperplasia of mucous epithelium and a widespread de-
position of hyaline-like materials were found throughout
the lamina propria, especially around blood vessels
(Figure 3A). The materials were positive for periodic-
acid–Schiff (PAS) stains (Figure 3B).
Mutation analysis identified a major allele in Chinese
patients with LP
Amplified DNA from the patient disclosed a homozygous
T substitution to G at nucleotide 658 (c.658 T >G) in the
exon 6 of the ECM1 gene (Figure 4). This mutation con-
verted cysteine to glycine, designated p.C220G. The par-
ents were heterozygous for this mutation, which was not
detected in 100 control genome DNAs (Figure 4A–D).
Literature analysis showed that in all reported eight
Chinese patients from five unrelated families (Table 2),
seven patients were found carrying the p.C220G muta-
tion, accounting for 75% of disease allele. Five of them
are homozygous and two are heterozygotes with com-
pound mutations (p.C220G and p.R476X). Only one
patient/family showed a different homozygous mutation
(p.C450R). Also, the p.C220G mutation is predicted to
be a damaging mutation by the Polyphen-2 program,
suggesting it is a major rare causative mutation in Chinese
patients. Furthermore, none of these three types of muta-
tions have been found in the SNP database, Human Gen-
ome 1000 or in an additional 156 normal Chinese exome
sequence database.
Clinical treatment
Based upon previous experience on treating lipid depos-
ition diseases with glucocorticoids (see Additional file 3),
we initiated a clinical treatment with a modified protocol
for the patient (see Additional file 2). After 1 year of oral
submucous injection and 2 years of oral and local appli-
cation of glucocorticoid, the patient’s symptoms were
significantly improved. His stiff underlip and lingual mu-
cosa became softening; his hoarse voice returned to nor-
mal. The waxy, yellow papules and the deepening fine
line on the forehead as well as the rugged scars on theTable 2 Mutation analysis of Chinese patients with LP
Patient number Mutation position Mutation type
Two siblings p.C220G Homozygous
Two siblings p.C220G; p.R476X Compound heterozygous
Two siblings p.C220G Homozygous
One p.C477R* Homozygous
One p.C220G Homozygous
Total: 8 7 patients p.C220G
Notes: Additional 18 cases were clinically described as LP, but specific ECM1 mutati
(GenBank acc. no., NP_004416.2), the mutation should be named as p.C450R.left shoulder became flat, smooth and lightened
(Figure 1C, D). No side effects were observed. Results of
the hematological examination returned to the normal
ranges except for a slightly higher basophilic granulocyte
level (Table 1). Several other laboratory tests were also
dramatically improved (see Additional files 4 & 5).
Conclusion
Lipoid proteinosis is characterized by various degrees of
scarring and infiltration of skin and mucosae [1,9]. The
typical clinical features include hoarseness, beaded eyelid
papules, mucosae infiltration of the pharynx, tongue, soft
palate, tonsils and lips [10,11]. In addition, the fragile
skin may be easily damaged by minor trauma or friction,
resulting in blisters and scar formation. All of these
could be found in our case. Furthermore, histopatho-
logical findings of periodic acid–Schiff (PAS)-positive,
and deposition or accumulation of hyaline materials in
the lamina propria, as well as irregular hyperplasia of
epithelium also strongly supported our diagnosis. To
date, at least 47 different mutations in the ECM1 gene
have been reported for more than 50 unrelated patients
with LP [3]. Most of them were family specific except
for the largest groups of LP patients worldwide in
Namaqualand, South Africa, suggesting a founder effect
[12]. Approximately half of all mutations (22 of 47) were
located within exon 6 or 7, suggesting a hot spot of muta-
tions for this disorder. In this study, we identified a homo-
zygous mutation also located on the exon 6 (c.658 T >G),
which was previously observed in three additional unre-
lated Chinese families [4]. Since this mutation has not
been detected in patients from any other races, it may rep-
resent an ancestral allele in Chinese Han population.
The human ECM1 gene was isolated in 1997 and
mapped to chromosome 1q21 [13]. ECM1 can stimulate
blood vessel endothelial cell proliferation and angiogen-
esis. Within the epidermis, however, ECM1 is able to in-
fluence the differentiation of keratinocyte. After secreted
into the dermis, ECM1 acts as a “biological glue” by
binding to glycosaminoglycans and fibrillar protein
growth factors, and then regulates basement membrane
and interstitial collagen fibril macro-assembly and growthParents marriage Hospital location Ref.
Unknown Xi’an Wang et al. [4]
Non-consanguineous Shanghai Wang et al. [5]
Unknown Shanxi Han et al. [6]
Non -consanguineous Beijing Liu et al. [7]
Non -consanguineous Xi’an This study
ons were not determined [8]. *According to the updated reference sequence
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ECM1 gene may induce a strange pattern of keratinocyte
maturation and differentiation, as well as dysregulation of
dermal homeostasis and clinical features of skin infiltra-
tion and scarring [12,14] (see Additional file 6).
Although many therapeutic trials have been tested to
alleviate LP symptoms, including oral steroids, oral di-
methyl sulphoxide (DMSO) and intralesional heparin, as
well as D-penicillamine and acitretin [9,15-17], no con-
vincing evidence has been found to support any sus-
tained treatment benefits. In our study, local injection of
compound betamethasone and oral application of hydro-
cortisone have dramatically alleviated the patient’s
symptoms such as thickened mucosa and recurrent ana-
phylaxis, and the treatment was well tolerated. We pos-
tulate that one of the possible mechanisms underlying it
might be associated with the inhibitory effects of gluco-
corticoid on the matrix metalloproteinases (MMP-9)
functions. Firstly, anaphylaxis with elevated IgE may ac-
tivate mast cell to secrete tumor necrosis factor alpha
(TNF-α) and to induce the proMMP-9 to be an active
enzyme [18]. Secondly, the activated mast cell will fur-
ther induce the MMP-9 to be released from fibroblasts
through both adhesive interactions and the release of
TNF-α from mast cells itself [19,20]. Thirdly, MMP-9
activation and overproduction are proved to be associ-
ated with the occurrence and development of some in-
flammatory reaction and anaphylaxis [21,22]. We thus
assume that the application of glucocorticoid, by targeting
the MMP-9 molecule, a key mediator in both LP and ana-
phylaxis, as well as in some inflammations, would alleviate
the anaphylactic reaction in skin and mucosa lesions in
LP. The postulated mechanism underling the effect of
glucocorticoid on LP patients is shown (see Additional file
6). However, further experiments and prospective, ran-
domized, controlled clinical trials are in need to verify this
hypothesis and long-term therapeutic effects as well as the
safety of glucocorticoid for treatment of LP.
In summary, we identified a hot C220G mutation of
the ECM1 gene in a child with LP, suggesting a founder
effect for this allele in Chinese patients. More import-
antly, modified glucocorticoid application can signifi-
cantly improve the symptoms of the patient suffering
from LP and recurrent anaphylaxis with no side effects.
Our experience and therapeutic protocol could be ap-
plied and verified in appropriate LP patients particularly
complicated with recurrent anaphylaxis or associated
chronic inflammation.Additional files
Additional file 1: Primers used for PCR amplification of the ECM1 gene.
Additional file 2: Protocol of Treatment for the patient with LP.Additional file 3: Lipid deposition disease treated with
glucocorticoids.
Additional file 4: Blood cell analysis before and after the three
years clinical treatment.
Additional file 5: Immunoglobulins, autoantibodies and T lymphocyte
subsets in blood serum before and after the three years clinical
treatment.
Additional file 6: A postulated mechanism of the treatment by
glucocorticoid. IgE, immunoglobulin E; TNF-α, tumor necrosis factor-α;
MMP-9, matrix metalloproteinase 9; ECM1, extracellular matrix protein.
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